Psykey, Inc. CEOS OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • CA • USD

Psykey, Inc. (CEOS) generated $2.13M in operating cash flow for fiscal year 2024. After capital expenditures of $78.66K, free cash flow was $2.05M.

Free cash flow margin was 32.6% of revenue. Cash conversion ratio was -6.07x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (0/100, Fail) — weak cash flow raises concerns about debt servicing
MOAT (50/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
INCOME (10/100) — Cash conversion ratio was -6.07x suggests some earnings are non-cash items

Overall SharesGrow Score: 22/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

24/100

SG Score

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

50/100

Proven by this page

GROWTH

58/100

→ Income

✗

INCOME

10/100

→ Income

Psykey, Inc. Cash Flow History

Metric	TTM	FY2024	FY2023	FY2022	FY2021
Operating Cash Flow	$964.81K	$2.13M	$159.76K	$-92.89K	$-92.31K
Capital Expenditure	$-123.24K	$-78.66K	$-159.76K	$0.00	$0.00
Free Cash Flow	$841.57K	$2.05M	$0.00	$-92.89K	$-92.31K